Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials-Reference-Cited by-同舟云学术

Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials

Published:2015-05 Issue:5 Volume:2 Page:e186-e193
ISSN:2352-3026
Container-title:The Lancet Haematology
language:en
Short-container-title:The Lancet Haematology

Author:

Sasaki Koji,Strom Sara S,O'Brien Susan,Jabbour Elias,Ravandi Farhad,Konopleva Marina,Borthakur Gautam,Pemmaraju Naveen,Daver Naval,Jain Preetesh,Pierce Sherry,Kantarjian Hagop,Cortes Jorge E

Funder

MD Anderson Cancer Center

National Cancer Institute

Publisher

Elsevier BV

Subject

Hematology

Reference39 articles.

1. Survival benefit with imatinib mesylate versus interferon-alpha-based regimens in newly diagnosed chronic-phase chronic myelogenous leukemia;Kantarjian;Blood,2006

2. Nilotinib is associated with a reduced incidence of BCR-ABL mutations vs imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase;Hochhaus;Blood,2013

3. Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial DASISION;Kantarjian;Blood,2012

4. Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial;Cortes;J Clin Oncol,2012

5. Ponatinib in refractory Philadelphia chromosome-positive leukemias;Cortes;N Engl J Med,2012

Cited by 239 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Structure‐Guided Drug Design Targeting Abl Kinase: How Structure and Regulation Can Assist in Designing New Drugs;ChemBioChem;2024-09-12

2. Evaluation of contraception methods in chronic myeloid leukemia patients: A Turkish multicenter study;Journal of Oncology Pharmacy Practice;2024-09-02

3. Atrial fibrillation in cancer, anticancer therapies, and underlying mechanisms;Journal of Molecular and Cellular Cardiology;2024-09

4. Critical review of clinical data and expert-based recommendations for the use of bosutinib in the treatment of chronic myeloid leukemia;Frontiers in Oncology;2024-08-26

5. Global burden, risk factor analysis, and prediction study of leukaemia from 1990 to 2030;Journal of Global Health;2024-08-23